Added 11 days ago Drug news
Coherus BioSciences, Inc.announced that Udenyca preliminary unaudited net sales for the quarter that ended March 31, 2019 are expected to...
Added 16 days ago Drug news
Sandoz, a Novartis division and a global leader in biosimilars, announced resubmission of its Biologics License Application (BLA) for a...
Added 3 months ago Drug news
Spectrum Pharmaceuticals announced that the company submitted a Biologics License Application (BLA) with the FDA for Rolontis (eflapegrastim) for chemotherapy-induced...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
Febrile neutropaenia is the development of fever, often with other signs of infection, in a patient with neutropaenia, an abnormally low number of neutrophil granulocytes in the blood.
Added 9 years ago
This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care.
Added 6 years ago
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.
Ascertainment of cases and disease classification is an acknowledged problem for epidemiological research into haematological malignancies.
Added 1 year ago
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Background: Hypomethylating drugs are the standard treatment for patients with high-risk myelodysplastic syndromes. Survival is poor after failure of these...
Added 3 years ago